Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats

Hypertension

Volumn 34, Issue 2, 1999, Pages 279-284

  Matsumoto, Keiko ^b   Morishita, Ryuichi ^a   Moriguchi, Atsushi ^b   Tomita, Naruya ^b   Yo, Yoshikage ^b   Nishii, Tadahiko ^b   Matsumoto, Kunio ^b   Nakamura, Toshikazu ^b   Higaki, Jitsuo ^b   Ogihara, Toshio ^b  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NONE

Author keywords

Angiotensin II; Angiotensin converting enzyme inhibitors; Hypertension, renal; Kidney tubules; Mesangium

Indexed keywords

4' [(2 CYCLOPROPYL 7 METHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL][1,1' BIPHENYL] 2 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; SCATTER FACTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; EPITHELIUM CELL; HISTOPATHOLOGY; HYPERTENSION; KIDNEY INJURY; MALE; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0032870244     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.34.2.279     Document Type: Article

References (38)

1. Erley CM, Haefele U, Heyne N, Braun N, Risler T. Microalbuminuria in essential hypertension: reduction by different antihypertensive drugs. Hypertension. 1993;21:810-815.
2. Ritz E, Orth SR, Strzelczyk P. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. J Hypertens. 1997;15:S21-S26.
3. Amann K, Nichols C, Tornig J, Schwarz U, Zeier M, Mall G, Ritz E. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant. 1996;11:1003-1011.
4. Masson GMC, Mikasa A, Yasuda H. Experimental vascular disease caused by aldosterone and renin. Endocrinology. 1962;71:505-512.
5. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED Jr. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med. 1972;52:633-652.
6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
7. van Hout BA, Simeon GP, McDonnell J, Mann JF. Economic evaluation of benazepril in chronic renal insufficiency. Kidney Int Suppl. 1997;63: S159-S162.
8. Kohara K, Mikami H, Okuda N, Higaki J, Ogihara T. Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat. Hypertension. 1993;21:975-979.
9. Camargo MJF, von Lutterotti N, Pecker MS, James GD, Timmermans PB, Laragh JH. DuP 753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet. Am J Hypertens. 1991;4: 341S-345S.
10. Fenoy FJ, Milicic I, Smith RD, Wong PC, Timmermans PB, Roman R. Effects of DuP 753 on renal function of normotensive and spontaneously hypertensive rats. Am J Hypertens. 1991;4:321S-326S.
11. Floege L, Eng E, Yopung BA, Johenson RJ. Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney Int. 1993;39:S47-S54.
12. Harris RC, Martinez-Maldonado M. Angiotensin II-mediated renal injury. Miner Electrolyte Metab. 1995;21:328-335.
13. Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int. 1997;52:1497-1510.
14. Yayama K, Matusi T, Takano M, Hayashi K, Nagamatsu T, Suzuki Y, Okamoto H. Activation of the renin-angiotensin system in anti-glomerular basement membrane antibody-induced glomerulonephritis. Biol Pharm Bull. 1995;18:411-415.
15. Lai KN, Leung JC, Lai KB, To WY, Yeung VT, Lai FM. Gene expression of the renin-angiotensin system in human kidney. J Hypertens. 1998;16: 91-102.
16. Yo Y, Morishita R, Yamamoto K, Tomita N, Kida I, Hayashi S, Moriguchi A, Kato S, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Actions of hepatocyte growth factor as a local modulator in the kidney: potential role in pathogenesis of renal disease. Kidney Int. 1998;53.50-58.
17. Nakamura T, Hagiya M, Nishizawa T, Seki T, Shimonishi M, Sugiura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440-443.
18. Matsumoto K, Nakamura T. Emerging multipotent aspect of hepatocyte growth factor. J Biochem. 1996;119:591-600.
19. Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol. 1994;127:1783-1787.
20. Ohmichi H, Koshimizu U, Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development. Development. 1998;125:1315-1324.
21. Igawa T, Matsumoto K, Kanda S, Saito Y, Nakamura T. Hepatocyte growth factor may function as a renotropic factor for regeneration in rats with acute renal injury. Am J Physiol. 1993;265:F425-F434.
22. Kawaida K, Matsumoto K, Shimazu H, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci U S A. 1994;91:4357-4361.
23. Miller SB, Martin DR, Kissane J, Hammerman MR. Hepatocyte growth factor accelerates recovery from acute ischemic renal injury in rats. Am J Physiol. 1994;266:F129-F134.
24. Mizuno S, Kurosawa T, Matsumoto K, Mizuno-Horikawa Y, Okamoto M, Nakamura T. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest. 1998;101:1827-1834.
25. Matsumiya G, Shirakura R, Miyagawa S, Izutani H, Sawa Y, Nakata S, Matsuda H. Analysis of rejection in the rat to mouse cardiac xenotransplantation: role and characteristics of anti-endothelial cell antibodies. Transplantation. 1994;57:1653-1660.
26. Yo Y, Morishita R, Nakamura S, Tomita N, Yamamoto K, Moriguchi A, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Potential role of hepatocyte growth factor in the maintenance of renal structure: anti-apoptotic action of HGF on epithelial cells. Kidney Int. 1998;54:1128-1138.
27. Nakano N, Moriguchi A, Morishita R, Kida I, Tomita N, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor, in experimental hypertensive rats. Hypertension. 1997;30:1448-1454.
28. Obata J, Nakamura T, Kuroyanagi R, Yoshida Y, Guo DF, Inagami T. Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats. Kidney Int Suppl. 1997;63:S229-S231.
29. Yo Y, Moriguchi A, Higaki J, Nagano M, Nakano N, Kamide K, Yu H, Mikami H, Ogihara T. Renal effects of an angiotensin II antagonist in stroke-prone spontaneously hypertensive rat. Nephron. 1997;76: 466-471.
30. Nakano N, Morishita R, Moriguchi A, Nakamura Y, Hayashi S, Aoki M, Kida I, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Negative regulation of local hepatocyte growth factor (HGF) expression by angiotensin II and transforming growth factor-β in blood vessels: potential role of HGF in cardiovascular disease. Hypertension. 1998; 32:444-451.
31. Morishita R, Nakamura S, Nakamura Y, Aoki M, Moriguchi A, Kida I, Yo Y, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Potential role of endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes mellitus. Diabetes. 1997;46:138-142.
32. Morishita R, Higaki J, Hayashi S, Yo Y, Aoki M, Nakamura S, Moriguchi A, Matsushita H, Matsumoto K, Nakamura T, Ogihara T. Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor. Diabetologia. 1997;40:1053-1061.
33. Vercellotti GM, Tolins JP. Endothelial activation and the kidney: vaso-mediator modulation and antioxidam strategies. Am J Kidney Dis. 1993; 21:331-343.
34. Lee LK, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest. 1995;96:953-964.
35. Rigotti P, Ferraresso M, Morpurgo E, Cardrobbi R, Menon F, Bacelle L, Calabrese F, Valente ML. Gatta A, Ancona E. Prevention of renal ischemic injury by endothelial protecting agents. Transplant Proc. 1995;27: 749-751.
36. Schena FP. Role of growth factors in acute renal failure. Kidney Int. 1998;66: S11-S15.
37. Nakamura Y, Morishita R, Nakamura S, Aoki M, Moriguchi A, Matsumoto K, Nakamura T, Higaki J, Ogihara T. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension. 1996;28:409-413.
38. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, Yamada K. Hayashi S, Yo Y, Nakano H, Matsumoto K, Nakamura T, Ogihara T. Hepatocyte growth factor (HGF) is a novel member of endothelium-specific growth factors: additive stimulatory effect of HGF with basic fibroblast growth factor, but not vascular endothelial growth factor. J Hypertens. 1996;14:1067-1072.